Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 207.63K P/E - EPS this Y - Ern Qtrly Grth -
Income -12.26M Forward P/E - EPS next Y - 50D Avg Chg -68.00%
Sales 500k PEG - EPS past 5Y - 200D Avg Chg -79.00%
Dividend N/A Price/Book 0.02 EPS next 5Y - 52W High Chg -94.00%
Recommedations - Quick Ratio 0.16 Shares Outstanding 64.36M 52W Low Chg -
Insider Own - ROA -4.22% Shares Float - Beta -0.33
Inst Own - ROE -125.15% Shares Shorted/Prior -/- Price 0.00100
Gross Margin 100.00% Profit Margin - Avg. Volume 3,748 Target Price -
Oper. Margin -141.95% Earnings Date - Volume 300 Change 0.00%

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.